Shiling Hu

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Inhibition of delayed rectifier K+ channels by dexfenfluramine (Redux)
    S Hu
    Research Department, Novartis Pharmaceuticals Corp, Summit, New Jersey, USA
    J Pharmacol Exp Ther 287:480-6. 1998
  2. ncbi Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell
    S Hu
    Metabolic Cardiovascular Diseases, Novartis Institute for Biomedical Research, 556 Morris Avenue, Summit, NJ 07901, USA
    Eur J Pharmacol 427:97-104. 2001
  3. ncbi Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action
    Shiling Hu
    Metabolic Cardiovascular Diseases, Research Department, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Eur J Pharmacol 442:163-71. 2002
  4. pmc Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Int J Exp Diabetes Res 2:63-72. 2001
  5. pmc Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Int J Exp Diabetes Res 2:73-9. 2001
  6. ncbi The mechanisms underlying the unique pharmacodynamics of nateglinide
    S Hu
    Novartis Institute for Biomedical Research, 556 Morris Avenue, LSB 2287 Summit, NJ 07901, USA
    Diabetologia 46:M37-43. 2003
  7. ncbi Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
    S Hu
    Metabolic and Cardiovascular Disease Department, Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA
    J Pharmacol Exp Ther 293:444-52. 2000
  8. ncbi Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, New Jersey 07901 1027, USA
    J Pharmacol Exp Ther 291:1372-9. 1999
  9. ncbi Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720
    Fumin Fu
    Novartis Institute for Biomedical Research, Summit, New Jersey Novartis Pharma AG, Basel, Switzerland
    Transplantation 73:1425-30. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Inhibition of delayed rectifier K+ channels by dexfenfluramine (Redux)
    S Hu
    Research Department, Novartis Pharmaceuticals Corp, Summit, New Jersey, USA
    J Pharmacol Exp Ther 287:480-6. 1998
    ..The common inhibitory effect on DRK channels in oral taste cells and cardiac cells by this class of compounds might contribute to the anorectic and some of the detrimental cardiovascular effect associated with long-term exposure...
  2. ncbi Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell
    S Hu
    Metabolic Cardiovascular Diseases, Novartis Institute for Biomedical Research, 556 Morris Avenue, Summit, NJ 07901, USA
    Eur J Pharmacol 427:97-104. 2001
    ..The direct effects of these antidiabetic agents on Kv and Ca(2+) channels may act concertedly with their primary action on K(ATP) channels in regulating [Ca(2+)](i) and the stimulus-secretion coupling...
  3. ncbi Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action
    Shiling Hu
    Metabolic Cardiovascular Diseases, Research Department, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Eur J Pharmacol 442:163-71. 2002
    ..The data provide mechanistic rationale for the unique in vivo and ex vivo activity profile of nateglinide and may contribute to reduced hypoglycemic potential associated with excessive insulin secretion...
  4. pmc Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Int J Exp Diabetes Res 2:63-72. 2001
    ..Further, the present findings suggest that nateglinide may exert a more physiologic effect on insulin secretion than comparator agents and thereby have less propensity to elicit hypoglycemia in vivo...
  5. pmc Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Int J Exp Diabetes Res 2:73-9. 2001
    ..The insulinotropic efficacy of NAT in islets desensitized to SUs may result from a distinct receptor/effector mechanism, which contributes to the unique pharmacological profile of NAT...
  6. ncbi The mechanisms underlying the unique pharmacodynamics of nateglinide
    S Hu
    Novartis Institute for Biomedical Research, 556 Morris Avenue, LSB 2287 Summit, NJ 07901, USA
    Diabetologia 46:M37-43. 2003
    ..Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia...
  7. ncbi Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
    S Hu
    Metabolic and Cardiovascular Disease Department, Novartis Institute for Biomedical Research, Summit, New Jersey 07901, USA
    J Pharmacol Exp Ther 293:444-52. 2000
    ..These results suggest that the unique characteristics of nateglinide are largely the result of its interaction at the K(ATP) channel...
  8. ncbi Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels
    S Hu
    Metabolic and Cardiovascular Diseases, Novartis Institute for Biomedical Research, Summit, New Jersey 07901 1027, USA
    J Pharmacol Exp Ther 291:1372-9. 1999
    ..These data collectively indicate that NAT, when compared with GLY and REP, at concentrations effective in stimulating insulin secretion is least likely to cause detrimental CV effects via blockade of CV K(ATP) channels...
  9. ncbi Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720
    Fumin Fu
    Novartis Institute for Biomedical Research, Summit, New Jersey Novartis Pharma AG, Basel, Switzerland
    Transplantation 73:1425-30. 2002
    ..This study was designed to assess the efficacy of FTY720, a novel immunomodulator with a unique mechanism of action, on islet graft survival and function in streptozotocin (STZ)- and autoimmune-induced diabetic recipients...